17 research outputs found
Cancer genomics paves the way to targeted therapy.
RESUMEN: La lucha contra el cáncer es aún un desafío mayor, con cerca de 14 millones de nuevos casos de cáncer al año y más de 8 millones de muertes anuales atribuidas al cáncer. Con la ayuda de múltiples servicios clínicos del HUMV y otras Instituciones, trabajamos para demostrar la hipótesis de que análisis integrados de genómica y secuenciación dirigida de alta profundidad en especímenes quirúrgicos de rutina puede generar datos firmes y relevantes sobre la complejidad molecular, composición subclonal, índice mutacional, firmas mutacionales y mutaciones precisas en genes con implicaciones terapéuticas; así generando una herramienta diagnóstica robusta que permita predecir sensibilidad a terapias específicas. In este proyecto, hemos podido demostrar que los estudios genómicos del cáncer demuestran dianas útiles para la intervención terapéutica y que la combinación de múltiples terapias inactivando rutas oncogénicas convergentes representa una opción plausible para pacientes con cáncer avanzado.ABSTRACT: Cancer is still a mayor challenge with something more than 14M new cases per year in the world and more of 8M patients dying yearly because of cancer. With the collaboration of multiple clinical services at the HUMV and other clinical institutions, we are working to demonstrate the hypothesis that genomics integrative analysis and high-depth targeted mutational analysis in routine cancer specimens may generate consistent, relevant data informing about molecular complexity, subclonal composition, mutational rate, mutational signatures and precise mutations in genes with therapeutic implications; thus generating a robust, solid, diagnostic tool that may allow to predict the sensitivity to specific therapies. In this project we have been able to demonstrate that cancer genome studies do demonstrate actionable targets, and that the combination of multiple therapies targeting convergent pathways represent a plausible option for advanced cancer patients
Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors
ackground & Aims
There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients.
Methods
Cross-sectional, case-control study included all consecutive IBD patients treated at 2 different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes status, and body mass index in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter. Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. In addition, age- and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group.
Results
Eight hundred thirty-one IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (transient elastography ≥9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (P < .001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted odds ratio, 1.99; P < .001) and an independent risk factor for advanced liver fibrosis (adjusted odds ratio, 5.55; P < .001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases, and fibrosis of any degree was confirmed in 25 of 40 cases (62.5%). Body mass index and type 2 diabetes prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD.
Conclusions
MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.Acknowledgements: The authors report funding support from the Spanish Instituto de Salud Carlos III-FEDER Grant (FIS - PI18/01304) related to this manuscript
Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. There is increasing interest in developing specific markers to serve as predictors of response to sorafenib and to guide targeted therapy. Using a sequencing platform designed to study somatic mutations in a selection of 112 genes (HepatoExome), we aimed to characterize lesions from HCC patients and cell lines, and to use the data to study the biological and mechanistic effects of case-specific targeted therapies used alone or in combination with sorafenib. We characterized 331 HCC cases in silico and 32 paired samples obtained prospectively from primary tumors of HCC patients. Each case was analyzed in a time compatible with the requirements of the clinic (within 15 days). In 53% of the discovery cohort cases, we detected unique mutational signatures, with up to 34% of them carrying mutated genes with the potential to guide therapy. In a panel of HCC cell lines, each characterized by a specific mutational signature, sorafenib elicited heterogeneous mechanistic and biological responses, whereas targeted therapy provoked the robust inhibition of cell proliferation and DNA synthesis along with the blockage of AKT/mTOR signaling. The combination of sorafenib with targeted therapies exhibited synergistic anti-HCC biological activity concomitantly with highly effective inhibition of MAPK and AKT/mTOR signaling. Thus, somatic mutations may lead to identify case-specific mechanisms of disease in HCC lesions arising from multiple etiologies. Moreover, targeted therapies guided by molecular characterization, used alone or in combination with sorafenib, can effectively block important HCC disease mechanisms.FUNDING: Grants from ISCIII, co-financed by the European Union (FEDER) (PI16/00156), Ramón and Cajal research program from MINECO (RYC-2013-14097) and FUNDACIÓN LUCHAMOS POR LA VIDA to JPV. Grants from ISCIII (RD06/0020/0107-RD012/0036/0060) to MAP. Grant from ISCIII (Ref. PIE15/00079) to JC & JPV. NGD is a recipient of a UC-IDIVAL pre-doctoral fellow. I.V. was also supported by the Ramón and Cajal research program
Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas
Merkel cell carcinoma (MCC) is a highly malignant neuroendocrine tumor of the skin whose molecular pathogenesis is not completely understood, despite the role that Merkel cell polyomavirus can play in 55e90% of cases. To study potential mechanisms driving this disease in clinically characterized cases, we searched for somatic mutations using whole-exome sequencing, and extrapolated our findings to study functional biomarkers reporting on the activity of the mutated pathways. Confirming previous results, Merkel cell polyomavirus-negative tumors had higher mutational loads with UV signatures and more frequent mutations in TP53 and RB compared with their Merkel cell polyomavirus-positive counterparts. Despite important genetic differences, the two Merkel cell carcinoma etiologies both exhibited nuclear accumulation of oncogenic transcription factors such as NFAT or nuclear factor of activated T cells (NFAT), P-CREB, and P-STAT3, indicating commonly deregulated pathogenic mechanisms with the potential to serve as targets for therapy. A multivariable analysis identified phosphorylated CRE-binding protein as an independent survival factor with respect to clinical variables and Merkel cell polyomavirus status in our cohort of Merkel cell carcinoma patients.This work was supported by grants from Instituto de Salud-Carlos III (ISCIII); cofinanced by the European Union; (FEDER) (PI12/00357), and a Ramón and Cajal research program (MINECO; RYC-2013-14097) to JPV, Asociación Española Contra el Cáncer and ISCIII grants (RD06/0020/0107, RD012/0036/0060) to MAP, and Coordinated Project of Excellence inter-Institutos de investigación acreditados institutes (ISCIII; PIE15/00081) to MAP. The Ramón and Cajal research program also supports IV. SD was supported by the Torres Quevedo subprogram (MICINN; PTQ-12-05391)
COVID-19 outbreaks in a transmission control scenario: challenges posed by social and leisure activities, and for workers in vulnerable conditions, Spain, early summer 2020
Severe acute respiratory syndrome coronavirus 2 community-wide transmission declined in Spain by early May 2020, being replaced by outbreaks and sporadic cases. From mid-June to 2 August, excluding single household outbreaks, 673 outbreaks were notified nationally, 551 active (>6,200 cases) at the time. More than half of these outbreaks and cases coincided with: (i) social (family/friends’ gatherings or leisure venues) and (ii) occupational (mainly involving workers in vulnerable conditions) settings. Control measures were accordingly applied
Medicina de precisión en el carcinoma de células de Merkel y el melanoma cutáneo avanzado: implicaciones de la caracterización molecular en el diagnóstico, el pronóstico y la terapia dirigida
[EN]: In this work, two types of aggressive skin cancer have been studied; Merkel cell carcinoma (MCC) and advanced cutaneous melanoma. Their study has been addressed starting with the molecular characterization of tumors by means of DNA sequencing techniques, whose results have been later used to develop potential translational applications to diagnosis and treatment. It has been designed a novel and original approach to molecularly characterize MCC tumors, consisting in a combination of mutational and immunohistochemical analysis. Such analysis has allowed the identification of new disease mechanisms, besides two adverse prognostic markers. Furthermore, it has been developed a targeted mutational analysis platform to characterize advanced cutaneous melanoma cases, in a time compatible with the clinic. As well, specific combinatorial therapies have been designed, which have shown a clear efficacy both ex vivo and in vivo.[ES]: En este trabajo se han estudiado dos tipos de cáncer de piel agresivos; el carcinoma de células de Merkel (MCC) y el melanoma cutáneo avanzado. Su estudio se ha abordado partiendo de la caracterización molecular de los tumores mediante el uso de técnicas de secuenciación de ADN, cuyos resultados se han utilizado posteriormente para desarrollar posibles aplicaciones traslacionales para el diagnóstico y el tratamiento. Se ha diseñado un abordaje novedoso y original para caracterizar molecularmente tumores de MCC, consistente en la combinación de análisis mutacionales e inmunohistoquímicos. Este análisis ha permitido identificar nuevos mecanismos de enfermedad, además de dos marcadores pronósticos adversos. También se ha desarrollado una plataforma de análisis mutacional dirigido para caracterizar casos de melanoma cutáneo avanzado al diagnóstico, en un tiempo compatible con la práctica clínica, y se han diseñado terapias de combinación específicas que han demostrado ser eficaces tanto ex vivo como in vivo.Peer Reviewe
Medicina de precisión en el carcinoma de células de Merkel y el melanoma cutáneo avanzado: implicaciones de la caracterización molecular en el diagnóstico, el pronóstico y la terapia dirigida
ABSTRACT: In this work, two types of aggressive skin cancer have been studied; Merkel cell carcinoma (MCC) and advanced cutaneous melanoma. Their study has been addressed starting with the molecular characterization of tumors by means of DNA sequencing techniques, whose results have been later used to develop potential translational applications to diagnosis and treatment.
It has been designed a novel and original approach to molecularly characterize MCC tumors, consisting in a combination of mutational and immunohistochemical analysis. Such analysis has allowed the identification of new disease mechanisms, besides two adverse prognostic markers. Furthermore, it has been developed a targeted mutational analysis platform to characterize advanced cutaneous melanoma cases, in a time compatible with the clinic. As well, specific combinatorial therapies have been designed, which have shown a clear efficacy both ex vivo and in vivo.RESUMEN: En este trabajo se han estudiado dos tipos de cáncer de piel agresivos; el carcinoma de células de Merkel (MCC) y el melanoma cutáneo avanzado. Su estudio se ha abordado partiendo de la caracterización molecular de los tumores mediante el uso de técnicas de secuenciación de ADN, cuyos resultados se han utilizado posteriormente para desarrollar posibles aplicaciones traslacionales para el diagnóstico y el tratamiento.
Se ha diseñado un abordaje novedoso y original para caracterizar molecularmente tumores de MCC, consistente en la combinación de análisis mutacionales e inmunohistoquímicos. Este análisis ha permitido identificar nuevos mecanismos de enfermedad, además de dos marcadores pronósticos adversos. También se ha desarrollado una plataforma de análisis mutacional dirigido para caracterizar casos de melanoma cutáneo avanzado al diagnóstico, en un tiempo compatible con la práctica clínica, y se han diseñado terapias de combinación específicas que han demostrado ser eficaces tanto ex vivo como in vivo.La financiación necesaria para la realización de esta tesis ha sido aportada por el
Ministerio de Economía y Competitividad (RD12/0036/0060), el Ministerio de
Educación y Ciencia (RD06/0020/0107), el Instituto de Investigación Carlos III
(PIE15/00081 y PI12/00357) y la asociación Luchamos por la Vida (LPLV-2015, LPLV-
2016)
Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations
Letter to Blood.-- Curiel-Olmo, Soraya et al.Splenic diffuse red pulp lymphoma (SDRPL) is a rare small B-cell neoplasm provisionally included in the category of unclassifiable splenic B-cell lymphomas/leukemias in the 2008 World Health Organization classification. SDRPL is characterized by a diffuse pattern of involvement of the splenic red pulp by small monomorphous B lymphocytes.This work was supported by grants from the Ministerio de Economía, Industria y
Competitividad (RTICC RD06/0020/0107, RD12/0036/0060, PI 12/1682, PT13/
0010/0007, PI16/01294, SAF2013-47416-R, CIBERONC-ISCIII, PIE15/0081) and the Asociación Española Contra el Cáncer, Spain. S.D. was supported by the Torres Quevedo subprogramme (Ministerio de Economía y Competitividad [MICINN]) under grant agreement PTQ-12-05391.Peer Reviewe
Osteomesopyknosis associated with a novel ALOX5 variant that impacts the RANKL pathway
Abstract Background Bone tissue homeostasis relies on the coordinated activity of the bone‐forming osteoblasts and bone‐resorbing osteoclasts. Osteomesopyknosis is considered a distinctive rare sclerosing skeletal disorder of unelucidated pathophysiology and presumably autosomal dominant transmission. However, the causal genes are unknown. Methods We present a case report encompassing clinical assessments, imaging studies, and whole‐exome sequencing analysis, complemented by functional in vitro experiments. Results This new case of osteomesopyknosis was associated with a missense ALOX5 variant predicted to induce protein misfolding and proteasomal degradation. Transfection experiments demonstrated that the variant was associated with reduced protein levels restored by proteasomal inhibition with bortezomib. Likewise, gene expression analysis showed that the mutated gene was associated with a decreased RANKL/OPG ratio, which is a critical driver of osteoclast precursor differentiation. Conclusion Our data indicate impaired bone resorption as the underlying mechanism of this rare osteosclerosis, implicating ALOX5 pathogenic variants as potential etiological factors